Research Topics
| Daniel J TenneySummaryAffiliation: Bristol-Myers Squibb Country: USA Publications
| Collaborators
|
Detail Information
Publications
Entecavir resistance is rare in nucleoside naïve patients with hepatitis BRichard J Colonno
Bristol Myers Squibb Pharmaceutical Research Institute, Wallingford, CT 06492, USA
Hepatology 44:1656-65. 2006..These findings suggest that the rapid, sustained suppression of HBV replication, combined with a requirement for multiple substitutions, creates a high genetic barrier to ETVr in nucleoside naïve patients...
Inhibition of hepatitis B virus polymerase by entecavirDavid R Langley
Bristol Myers Squibb Pharmaceutical Research Institute, 5 Research Parkway, Wallingford, CT 06443, USA
J Virol 81:3992-4001. 2007..Overall, these studies explain the potency, mechanism, and cross-resistance profile of ETV against HBV and account for the successful treatment of naive and LVD- or ADV-experienced chronic HBV patients...- Clinical emergence of entecavir-resistant hepatitis B virus requires additional substitutions in virus already resistant to LamivudineD J Tenney
Bristol Myers Squibb Pharmaceutical Research Institute, 5 Research Pkwy, Wallingford, CT 06492, USA
Antimicrob Agents Chemother 48:3498-507. 2004..In summary, infrequent ETV resistance can emerge during prolonged therapy, with selection of additional RT substitutions within a 3TC(r) HBV background, leading to reduced ETV susceptibility and treatment failure... 
Genotypic determinants and phenotypic properties of antiviral-resistant HBV variants: insight from entecavir resistance studiesDaniel J Tenney
Bristol Myers Squibb Research and Development, Wallingford, CT, USA
Antivir Ther 15:529-35. 2010..The scheme takes into account the need for rapid analysis of large numbers of clinical isolates through nucleotide sequencing and methods for phenotypic validation using cell culture and in vitro enzyme immunoassay formats...- Two-year assessment of entecavir resistance in Lamivudine-refractory hepatitis B virus patients reveals different clinical outcomes depending on the resistance substitutions presentDaniel J Tenney
Bristol Myers Squibb Pharmaceutical Research Institute, 5 Research Parkway, Wallingford, CT 06492, USA
Antimicrob Agents Chemother 51:902-11. 2007..In summary, ETV was effective in LVD-refractory patients, with resistant sequences arising from a subset of patients harboring preexisting LVDr/ETVr variants and with approximately half of the patients experiencing a virologic rebound... - Long-term monitoring shows hepatitis B virus resistance to entecavir in nucleoside-naïve patients is rare through 5 years of therapyDaniel J Tenney
Bristol Myers Squibb Company Research and Development, Wallingford, CT 06492, USA
Hepatology 49:1503-14. 2009..These findings support ETV as a primary therapy that enables prolonged treatment with potent viral suppression and minimal resistance... - Hepatitis B virus quasispecies susceptibility to entecavir confirms the relationship between genotypic resistance and patient virologic responseCarl J Baldick
Bristol Myers Squibb Research and Development, 5 Research Parkway, Wallingford, CT 06492, USA
J Hepatol 48:895-902. 2008..Using >500 patient HBV isolates from several entecavir clinical trials, we show that phenotypic susceptibility correlates with genotypic resistance and patient virologic responses... - Ultrasensitive genotypic detection of antiviral resistance in hepatitis B virus clinical isolatesJie Fang
Bristol Myers Squibb Research and Development, Wallingford, CT, USA
Antimicrob Agents Chemother 53:2762-72. 2009..In summary, we established and validated an ultrasensitive method for measuring resistant HBV variants in clinical specimens, which enabled earlier, quantitative measurement of resistance to therapy... - Comprehensive evaluation of hepatitis B virus reverse transcriptase substitutions associated with entecavir resistanceCarl J Baldick
Bristol Myers Squibb Research and Development, Wallingford, CT 06492, USA
Hepatology 47:1473-82. 2008.... - High-throughput screening and rapid inhibitor triage using an infectious chimeric Hepatitis C virusMichael J Wichroski
Bristol Myers Squibb Research and Development, Wallingford, Connecticut, United States of America
PLoS ONE 7:e42609. 2012..Leveraging results from this robust whole-virus assay represents a critical first step towards identifying inhibitors of novel targets to broaden the spectrum of antivirals for the treatment of HCV... - Entecavir for treatment of hepatitis B virus displays no in vitro mitochondrial toxicity or DNA polymerase gamma inhibitionCharles E Mazzucco
Bristol Myers Squibb Pharmaceutical Research Institute, 5 Research Parkway, Wallingford, CT 06492, USA
Antimicrob Agents Chemother 52:598-605. 2008..In summary, cell culture and enzymatic studies yielded no evidence that would predict mitochondrial toxicity of ETV at exposure levels in excess of those expected to be achieved clinically... - Entecavir therapy for lamivudine-refractory chronic hepatitis B: improved virologic, biochemical, and serology outcomes through 96 weeksMorris Sherman
Department of Medicine, Toronto General Hospital, Toronto, Ontario, Canada
Hepatology 48:99-108. 2008..CONCLUSION: Through 96 weeks of treatment, 1 mg entecavir resulted in continued clinical benefit in lamivudine-refractory HBeAg-positive chronic hepatitis B patients with a safety profile comparable to lamivudine...